P3-068: An economic analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21, a randomized trial of erlotinib versus best supportive care after cisplatin based chemotherapy in advanced non-small-cell lung cancer (NSCLC)

Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827

Revista Portuguesa de Pneumologia (English Edition) ◽

10.1016/s2173-5115(09)70132-0 ◽

2009 ◽

Vol 15 (3) ◽

pp. 555-559

Author(s):

Wojciech Bartminski

Keyword(s):

Lung Cancer ◽

Economic Analysis ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

Third Line ◽

Third Line Treatment

A prospective randomized trial of Taxotere versus best supportive care (BSC) in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy: Survival update

Lung Cancer ◽

10.1016/s0169-5002(00)80193-2 ◽

2000 ◽

Vol 29 (1) ◽

pp. 60 ◽

Author(s):

F Shepherd ◽

J Dancey ◽

R Ramlau ◽

K Mattson ◽

R Gralla ◽

...

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Randomized Trial ◽

Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Small Cell Lung ◽

Platinum Based Chemotherapy ◽

Previously Treated

A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer

Lung Cancer ◽

10.1016/0169-5002(92)90260-q ◽

1992 ◽

Vol 8 (1) ◽

pp. 60

Keyword(s):

Lung Cancer ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Randomized Trial ◽

Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Small Cell Lung ◽

Alternating Chemotherapy

Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer

Journal of Clinical Oncology ◽

10.1200/jco.20.5.1344 ◽

2002 ◽

Vol 20 (5) ◽

pp. 1344-1352 ◽

Cited By ~ 35

Author(s):

N. B. Leighl

Keyword(s):

Lung Cancer ◽

Economic Analysis ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy

Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827

Revista Portuguesa de Pneumologia (English Edition) ◽

10.1016/s2173-5115(09)70133-2 ◽

2009 ◽

Vol 15 (3) ◽

pp. 560-566

Author(s):

António Araújo

Keyword(s):

Lung Cancer ◽

Economic Analysis ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

Third Line ◽

Third Line Treatment

An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer

Revista Portuguesa de Pneumologia (English Edition) ◽

10.1016/s2173-5115(08)70309-9 ◽

2008 ◽

Vol 14 (6) ◽

pp. 803-827 ◽

Author(s):

A. Araújo ◽

B. Parente ◽

R. Sotto-Mayor ◽

E. Teixeira ◽

T. Almodôvar ◽

...

Keyword(s):

Lung Cancer ◽

Economic Analysis ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

Third Line ◽

Third Line Treatment

PD-064 Are age and co morbidity independent prognostic factors in thetreatment of metastatic non-small cell lung cancer (NSCLC): A review of a national cancer institute of Canada clinical trials group (NCIC-CTG) randomized trial

Lung Cancer ◽

10.1016/s0169-5002(05)80397-6 ◽

2005 ◽

Vol 49 ◽

pp. S85 ◽

Author(s):

T. Asmis ◽

K. Ding ◽

F. Shepherd ◽

N. Leighl ◽

L. Seymour ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trials ◽

Prognostic Factors ◽

Small Cell Lung Cancer ◽

Randomized Trial ◽

Cell Lung Cancer ◽

National Cancer Institute ◽

Small Cell ◽

Small Cell Lung ◽

Co Morbidity

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome

British Journal of Cancer ◽

10.1054/bjoc.2000.1307 ◽

2000 ◽

Vol 83 (4) ◽

pp. 447-453 ◽

Cited By ~ 238

Author(s):

H Anderson ◽

P Hopwood ◽

R J Stephens ◽

N Thatcher ◽

B Cottier ◽

...

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Randomized Trial ◽

Primary Outcome ◽

Best Supportive Care ◽

Small Cell ◽

Vinorelbine (VNR) plus best supportive care (BSC) vs. BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial

Lung Cancer ◽

10.1016/s0169-5002(98)90065-4 ◽

1998 ◽

Vol 21 ◽

pp. S33-S34 ◽

Cited By ~ 1

Author(s):

C Gridelli ◽

GP Ianniello ◽

L Maiorino ◽

L Brancaccio ◽

S Cigolari ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Randomized Trial ◽

Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Phase Iii ◽

PCN52 ECONOMIC ANALYSIS OF ERLOTINIB, DOCETAXEL, PEMETREXED AND BEST SUPPORTIVE CARE AS 2ND OR 3RD LINE TREATMENT OF NON-SMALL CELL LUNG CANCER

Value in Health ◽

10.1016/s1098-3015(10)66588-6 ◽

2008 ◽

Vol 11 (6) ◽

pp. A476 ◽

Author(s):

F Negreiro ◽

C Pereira ◽

H Pereira ◽

C Silva

Keyword(s):

Lung Cancer ◽

Economic Analysis ◽

Supportive Care ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Best Supportive Care ◽

Small Cell ◽

Line Treatment ◽